Jayachandran Muthukumaran
Division of Science and Technology, Beijing Normal University-Hong Kong Baptist University, United International College, 28, Jinfeng Road, Tangjiawan, Zhuhai- 519085, Guangdong. China.
Curr Pharm Des. 2017;23(16):2356-2365. doi: 10.2174/1381612823666170329124852.
Hepatocellular carcinoma (HCC) is the vital cause of cancer -related death throughout the world. At present, the exact mechanism responsible for the formation of HCC and its maintenance remains suspicious. Hepatocarcinogenesis involves a multistep activity involving several genetic aberrations which result in malignant transformation of the liver cells. The prevalence and occurrence of this disease are kept on increasing and an increase in the liver transplantation cases are vital indications for it. In the past decades, significant progress has been achieved toward the better elucidation of molecular pathways of oncogenic processes. Several, cell signaling mechanisms involved in tumor pathogenesis have been identified, leading to the production of new tumor markers and to set targets for therapy, including cytokines, enzymes, proteantigens. However, more tumor markers are in need for the effective early diagnosis of the disease condition and monitor the treatment efficacy. This review updates the recent findings in key molecular markers, pathways involved, animal models and treatment strategies in HCC and the advances obtained from basic research and clinical studies.
肝细胞癌(HCC)是全球癌症相关死亡的重要原因。目前,导致HCC形成及其维持的确切机制仍不明确。肝癌发生涉及多步骤活动,包括多个基因畸变,这些畸变导致肝细胞发生恶性转化。该疾病的患病率和发病率持续上升,肝移植病例的增加是其重要指征。在过去几十年中,在更好地阐明致癌过程的分子途径方面取得了重大进展。已经确定了几种参与肿瘤发病机制的细胞信号传导机制,从而产生了新的肿瘤标志物并为治疗设定了靶点,包括细胞因子、酶、蛋白抗原。然而,为了有效早期诊断疾病状况并监测治疗效果,还需要更多的肿瘤标志物。本综述更新了HCC关键分子标志物、相关途径、动物模型和治疗策略的最新研究结果,以及基础研究和临床研究取得的进展。